Advanced age adversely affects the prognosis of patients with hematologic malignancies and solid tumors. The lower survival rates of older patients with cancer compared with those of their younger counterparts are attributed to poorer-risk disease, multidrug-resistance mechanisms, low bone marrow reserves that prevent or delay recovery of hematopoiesis after treatment, and higher rates of comorbidities. Additionally, anemia may play an important role in the outcomes of elderly patients with cancer. The incidence of anemia increases with age and ranges from 3% to 11% in individuals older than 65 years.[2,3]The significance of anemia in elderly patients with cancer is evidenced by increased mortality rates, reduced cognitive function, increased risk of congestive heart failure, fatigue, and dependence, increased risk of chemotherapy-induced complications, reduced response of some cancers to certain treatment modalities, and increased number of red blood cell transfusions.
In this issue of ONCOLOGY, Balducci reviews the definition, incidence, and pathogenesis of anemia and its complications in the elderly. Balducci argues that the World Health Organization definition of anemia (hemoglobin levels lower than 12 g/dL in women and 13 g/dL in men) is arbitrary, does not account for ethnic differences, and may lead to the underdiagnosis of anemia and its causes, particularly in older women. The latter position is supported by studies demonstrating that a hemoglobin level of 13 g/dL in women is an independent risk factor for mortality and disability.[4,5]Balducci and others attribute the increase in the incidence and prevalence of anemia in the elderly not only to aging but also to the incidence and prevalence of chronic diseases causing anemia. Idiopathic anemia reportedly accounts for 15% to 30% of cases.
Mechanisms of Anemia
The current paper also attempts, in part, to determine the mechanisms and causes of anemia in older patients. The author suggests that the following mechanisms are responsible for anemia in the elderly: the development of resistance of erythropoietic precursors to erythropoietin(Drug information on erythropoietin) with aging and a decrease in the production of erythropoietin, which may be attributed to declining renal function, increased circulating cytokine levels, and exhaustion of erythropoietin production capability. The remaining cases of anemia in patients with cancer are caused by iron, cobalamine, and folate deficiency, hypothyroidism, chronic inflammation, and renal insufficiency. In particular, anemia in patients with cancer is attributed to six main causes: infection (13%-23%), chronic disease (17%-33%), iron deficiency (8%), nutritional deficiency (8%), chronic renal disease (8%-12%), and unexplained causes (18%-38%).Other investigators have reported that the expected inverse linear relationship between serum erythropoietin levels and hemoglobin was absent in cancer patients. They also showed that low erythropoietin levels may contribute to the development of cancer-related anemia. However, adequate erythropoietin production was restored in hypoxic patients with cancer.
Indications for Erythropoietic Therapy
Although the author recommends that the therapeutic goal in cancer patients with anemia should be to maintain hemoglobin levels of at least 12 g/dL, one is left with the question of whether it is reasonable to treat anemia in all older cancer patients with erythropoietic growth factors, given the increased risk of thromboembolic events. Further research is needed to determine specific indications for these growth factors in cancer patients. Previous reports have shown that although these agents have an established efficacy in reducing the need for red blood cell transfusions and improving the rates of hematologic response, their use is associated with an increased risk of thomboembolic events (eg, transient ischemic attacks, stroke, pulmonary emboli, deep-vein thrombosis, and myocardial infarction).